Summary
Several studies pointed out an altered stool pattern as the most common side effect of auranofin therapy. The major mechanism in the aetiology of auranofin-induced impairment in bowel habit seems to be the inhibition of Na+/K+ A TPase in the gut. In vitro experiments proved that auranofin can affect active bile acid (BA) reabsorption in rat terminal ileum; this action, due to the ability of the drug to reduce Na+ pump activity by inhibiting Na+/K+ATPase, may make a significant contribution to the auranofininduced diarrhoea. The ability of auranof in to reduce the Na+ gradient necessary for active BA reabsorption, however, could cause a decrease of serum BA levels in patients taking auranofin before or without the development of an overt diarrhoea. We measured fasting and postprandial serum conjugated BA levels in 10 female rheumatoid arthritis patients before and after one month and two months' auranofin treatment. No patient developed diarrhoea during the chrysotherapy. When oral gold salt therapy was started, we observed a slight decrease in serum BA levels, but difference was not statistically significant. We can conclude that auranofin therapy does not cause BA malabsorption in patients who do not develop diarrhoea during the treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rocha, M.P., Burrichter, P.J., Blodgett, R.C. Effect of chrysotherapy on the lower gastrointestinal tract: a review. Semin Arthritis Rheum 1987, 4, 294–99.
Dequeker, J., Verdickt, W., Gevers, G. et al. Longterm experience with oral gold in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 1984, 3, 67–73, (suppl. 1).
Lewis, D., Capell, H.A. Oral gold: a comparison with placebo and with intramuscular sodium aurothiomalate. Clin Rheumatol 1984, 3, 83–85, (suppl 1).
Menard, H.A., Beaudet, F., Davis, P. et al. Gold therapy in rheumatoid arthritis: interim report of the Canadian multi-center prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol 1982, 3, 179–183 (suppl 8).
Schattenkrichner, M., Kaik, B., Muller-Fassbender, H. et al. Auranofin and sodium aurothiomalate in the treatment in rheumatoid arthritis: a doubleblind, comparative multi-center study. J Rheumatol 1982, 9, 184–89, (suppl 8).
Smith, P.R., Brown, G.M.M., Meyers, O.L. An open comparative study of auranofin vs gold sodium thiomalate. J Rheumatol 1982, 9, 190–6 (suppl 8).
VanRiel, P.L.C.M., Van De Putte, L.B.A., Gribnau, F.W.J. et al. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single-blind study. Clin Rheumatol 1984, 3, 51–6, (suppl 1).
Williams, H.J., Ward, J.R., Egger, M.J. et al. Auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: cooperative systematic studies of rheumatic diseases. Clin Rheumatol 1984, 3, 39–50, (suppl 1).
Heuer, M.A., Pietrusko, R.D., Morris, R.W. et al. An analysis of wordwide safety experience with auranofin. J Rheumatol 1985, 12, 695–99.
Nechay, B.R. Inhibition of adenosine triphosphatases by gold. Arthritis Rheum 1980, 23, 464–70.
Fondacaro, J.D., Hendersen, L.S., Hardcastle, P.T., et al. Effect of auranofin (SKF 39162) on water and electrolyte flux in canine small bowel: a possible diarrheogenic mechanism. J Rheumatol 1986, 13, 288–93.
Hardcastle, J., Hardcastle, P.T., Kelleher, D.K., et al. Effect of auranofin on absorptive processes in the rat small bowel. J Rheumatol 1986, 13, 541–46.
Hardcastle, J., Hardcastle, P.T., Kelleher, D.K. et al. Effect of auranofin on the colonic transport of Na + and fluid in the rat. J Pharm Pharmacol 1986, 38, 466–68.
Hardcastle, J., Hardcasle, P.T., Kelleher, D.K. Auranofin inhibits the active uptake of bile acid by rat ileum. J Pharm Pharmacol 1987, 39, 572–3.
Binder, H.J., Editors: Fild, M., Fordtran, J.S., Schultz, S.G. In: Secretory diarrhea. American Physiological Society, Bethesda, Maryland, USA, 1980, pp. 159–178.
Linnet, K., Merz Nilsen, A. Fasting and postprandial serum concentrations of glycine and taurineconjugated bile acids in Crohn's disease. Scand J Gastroenterol 1983, 18, 433–38.
Kruis, W., Kalek, H.D., Stellaard, F. et al. Altered fecal bile acid pattern in patients with inflammatory bowel disease. Digestion 1988, 35, 189–98.
Spiller, R.C., Frost, P.F., Stewart, S.S. et al. Delayed postprandial plasma bile acid response in coeliac patients with slow mouth-caecum transit. Clin Sci 1987, 72, 217–23.
Stellaard, F., Sauerbruch, T., Luderschmidt, C.H., Leisner, B., Paumgartner, G. Intestinal involvement in progressive systemic sclerosis detected by increased unconjugated serum bile acids. Gut 1987, 28, 446–60.
Kim, Y.S., Spritz, M., Blum, M., Terz, J., Sherlock, P. The role of altered bile acid metabolism in the steatorrhea of experimental blind loop. J Clin Invest 1988, 45, 956–82.
Van Riel, P.L., Gribnau, F.W., Van De Putte, L.B. et al. Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities. J Rheumatol 1983, 10, 222–26.
Behrens, R., Devereaux, M., Hazelman, B. et al. Investigation of auranofin-induced diarrhea. Gut 1986, 27, 59–65.
Higgins, C.S., Moss, J., Woodrow, D. et al. Small intestine ultrastructure changes and auranofin treatment in rheumatoid arthritis. Br J Rheumatol 1986, 25, 227–29.
Hardcastle, J., Hardcastle, P.T., Kelleher, D.K. The effect of auranofin on intestinal transport mechanisms in the rat in vitro. J Physiol 1984, 354, 85 P.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magarò, M., Altomonte, L., Mirone, L. et al. Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients. Clin Rheumatol 9, 42–47 (1990). https://doi.org/10.1007/BF02030239
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02030239